Interesting insights on the use of GenAI in Healthcare, from Bayer's Guido Mathews, Medtronic's I...

Interesting insights on the use of GenAI in Healthcare, from Bayer's Guido Mathews, Medtronic's Irina Evstifeeva and Karista's Amine Benmoussa at Health Tech Forward in Barcelona.

Bayer has several use cases for GenAI. Drug discovery and compound development is one of them to improve time to market in collaboration with Google, and using LLMs to identify the right study design. In medical imaging they have an open platform for AI applications that is not exclusive to Bayer. As a concrete example, there are opportunities working with startups how contrast can be improved to shorten MRI scan times. They also see significant potential in the use of digital twins and synthetic control arms.

Karista sees significant clinical validation in the space of medical imaging while AI use cases in areas like drug discovery are still much more early stage. Initial validation of this technology will come from partnerships of techbio startups with Big Pharma and hospitals. However both targets are now inundated with proposals from startups.

At Medtronic there is significant focus on gaining efficacy in improving workflows with GenAI. At the same time concerns about how technology can ensure interoperability.